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Background - A potential role of dietary lipids in the management of hepatic glycogen storage 
disease (GSD) has been proposed, but no consensus on management guidelines exists. The 
aim of this study was to describe current experiences with dietary lipid manipulations in hepatic 
GSD patients.
Methods - An international study to identify published and unpublished cases describing hepatic 
GSD patients with a dietary lipid manipulation. A literature search was performed according to the 
Cochrane Collaboration methodology through PubMed and EMBASE (up to December 2018). All 
delegates who attended the dietetics session at the IGSD2017, Groningen were invited to share 
cases.
Results - 68 cases were collected, including GSDI (n=35), GSDIII (n=28), GSDVI (n=3) and GSDIX 
(n=2). Main indications were hyperlipidemia in GSDI and cardiomyopathy and/or myopathy in 
GSDIII. Most common interventions were medium-chain triglycerides (MCT) supplementation/ 
replacement in GSDI and high fat diet in GSDIII. 57% of the GSDI patients (but only 36% of children) 
showed a decline in triglycerides concentrations after MCT administration. In GSDIII patients a 
decline in creatine kinase concentrations (n=19, p<0.001) and a decrease in cardiac hypertrophy 
in pediatric GSDIIIa patients (n=7, p<0.01) were observed after high fat diet.
Conclusions - This study presents an international cohort of hepatic GSD patients with different 
dietary lipid manipulations. High fat diet may be beneficial in pediatric GSDIIIa patients with cardiac 
hypertrophy, but careful long-term monitoring for potential complications is warranted, such 
as growth restriction, liver inflammation and hepatocellular carcinoma development. The lipid 
lowering effect of MCT in GSDI requires further investigation.
SYNOPSIS
This international literature and retrospective international multi-center cohort study of dietary 
lipid manipulations in hepatic GSD patients presents positive (cardio)myopathy related outcomes 
observed after introduction with high fat diet in GSDIII patients and includes recommendations 
for future monitoring and scientific studies.
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INTRODUCTION
Glycogen storage diseases (GSD) are inborn errors of glycogen synthesis or degradation. Although 
a wide spectrum of clinical and biochemical presentation is observed, GSD are usually classified 
into hepatic and muscle GSD. Primary manifestations of the hepatic GSD subtypes 0, I, III, VI, IX 
and XI are fasting intolerance-associated hypoglycemia, hepatomegaly and failure to thrive. In 
addition, GSDIII patients also show a myopathic phenotype with skeletal muscle involvement 
and/or cardiomyopathy1.
Management guidelines have been published for GSD subtypes Ia 2,3, Ib4, III 5 and VI and IX 
together6. Dietary management is the cornerstone of treatment for hepatic GSD patients to maintain 
normoglycemia, prevent secondary metabolic derangements and long-term complications. Strict 
dietary management and compliance has significantly improved the outcomes for many GSD 
patients. Traditionally, dietary carbohydrates and protein have received most interest, whereas 
lipids usually have been restricted. Several case reports have described beneficial effects of dietary 
lipid manipulations in hepatic GSD patients, including (modified) ketogenic diets and medium-chain 
triglyceride (MCT) enrichment7–11. However, the role of dietary lipids as a third macronutrient in 
dietary management is still controversial12.
The aim of this study was to describe current experiences with dietary lipid manipulations in 
hepatic GSD patients. We performed a systematic literature study of all published cases describing 
hepatic GSD patients after dietary lipid manipulation. Thereafter, an international, observational, 
retrospective study was performed to include unpublished cases. The subsequent discussion 
provides recommendations for future patient care and research.
METHODS
Systematic literature study
Published cases were retrieved by a systematic literature search conducted according to the 
Cochrane Collaboration methodology on the 31st of December 2018. PubMed and EMBASE 
were searched using both MeSH terms and free text. A flowchart of the detailed search strategy 
can be found in Supplementary File A. All reports about hepatic GSD patients receiving dietary 
lipid manipulation were included. Inclusion criteria were GSD diagnosis based on biochemical or 
molecular evaluation and English language. Exclusion criteria were no individual data presentation 
and/or absence of follow-up data. Two independent reviewers (IJH, VBB) performed title, abstract 
screening and subsequently full-text assessment. After selection of eligible full-text papers and 
conference abstracts, case information was collected in a data table specifically designed for the 
purpose of this study, including patient’s age at start dietary intervention, gender, GSD subtype, 
indication to start dietary intervention, specifications of diet, duration of the intervention and follow-
up, and outcome measures (laboratory results, imaging tests and clinical picture).
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Unpublished cases were retrieved via the International GSD Conference 2017, organized in 
Groningen, The Netherlands on June 15-17, 2017. All metabolic dieticians were invited to join 
a networking session on the role of MCT in hepatic GSD. In October 2017, after the IGSD2017, 
all delegates who had attended the networking session received an invitation by email to share 
unpublished data of hepatic GSD patients with a dietary lipid manipulation. Data were collected 
through the same table used for published cases.
Data synthesis and analysis
Data on macronutrients were presented as energy percentage (E-%) of total caloric intake, or if 
otherwise noted in the legend. MCT supplementation was defined as regular GSD diet enriched 
in MCT. MCT replacement was defined as long-chain triglycerides substituted with MCT. High 
fat diet was defined as a diet in which lipids were the main macronutrient based on E-% values. 
Ketogenic diets were also categorized as high fat even in the absence of E-% values. Standard 
deviations of BMI were calculated using standard growth charts established by the CDC/2000. 
Age specific outcomes were presented as Z-scores or in subgroups (i.e. child and adult). The 
cutoff value for adulthood was set at 16 years of age. Laboratory parameters were presented as 
range (minimum-maximum value) before and after the dietary intervention, respectively. For each 
parameter, individual differences (Δ) were presented as percentage difference between mean values 
before and after the dietary intervention, respectively. Concentrations were considered increased 
when Δ > +10%, decreased when Δ < -10% and stable if Δ between -10% and +10%. Z-scores were 
calculated for interventricular septum dimensions (IVSd) to normalize for the body surface area. 
For Z-score calculation the regression equation by Pettersen was used13. The Haycock Formula 
was used for BSA calculation14.
Statistical analysis
Data were analyzed using Prism 7 software (GraphPad Software, Inc. La Jolla California USA) 
and SPSS, version 23.0 (IBM Corp., Armonk, New York, USA). Differences in outcome measures 
before and after dietary lipid manipulation were analyzed with a paired-t-test if data was 
normally distributed (assessed by the Shapiro–Wilk test). Non-normally distributed data was 
log-transformed to induce normal distribution. Data were analyzed with Wilcoxon signed ranks 
test in case of non-normally distributed data after log-transformation. Pearson’s or Spearman’s 
correlations test were used to define relationships between dietary parameters and changes in 
laboratory outcomes. Statistical significance was defined as p < 0.05.
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RESULTS
Cases
Literature search revealed nine full-text articles and six conference abstracts describing 37 
GSD patients (Supplementary File B), whereas 32 unpublished cases were collected from eight 
metabolic centers from four different countries (Supplementary File C). Data from case 17 was 
excluded from further data analysis, since case 17 and 18 likely represent the same patient15,16. 
Therefore, a total of 68 cases with hepatic GSD and a dietary lipid manipulation (35 GSDI, 28 GSDIII, 
3 GSDVI, 2 GSDIX) were collected.
Patients features, indication to start the diet and diet duration
Main patients’ features are presented in Table 1. The main indication to start the dietary intervention 
was hyperlipidemia in GSDI and muscle involvement in GSDIII. Eight patients (case 6, 29, 39, 47, 
48, 58, 65, and 66) did not follow the modified diet regimen regularly: either poor compliance was 
reported, or the diet was discontinued several times.
Diet composition
Most common lipid manipulations were MCT supplementation/replacement in GSDI and GSDIX, 
high fat diet in GSDIII patients, and corn oil supplementation in GSDVI (Table 1). Figure 1A-B 
presents the diet composition before and after dietary intervention in GSDI and GSDIII patients 
receiving MCT supplementation/replacement and high fat diet, respectively. MCT intake in GSDI 
patients ranged from 0.2 to 2.0 g/kg/day (0.4 - 2.0 g/kg/day in children, 0.2 - 0.5 g/kg/day in 
adults) (Figure 1C); lipid intake in GSDIII patients ranged from 0.9 to 8.0 g/kg/day (2.9 - 8.0 g/kg/
day in children, 0.9 - 2.7 g/kg/day in adults) (Figure 1D). Less common interventions included 
omega-3FA supplementation (cases 42-44), corn oil supplementation (cases 19, 34-37)17, and 
MCT supplementation alone in GSDIII (cases 26,27)18 and GSDIX (cases 68-69) (Supplementary 
files B-C).
4a
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GSDI GSDIII GSDVI GSDIX
Cases, n 35 28 3 2
Published 19 14 3 -
Unpublished 16 14 - 2
Gender, n (%)
Male 13 (37%) 11 (39%) 3 (100%) 2 (100%)
Female 10 (29%) 15 (54%) - -
Unknown 12 (34%) 2 (7%) - -
Age1, years
Median [range] 7 [0-36] 7 [0-41] 2 [1-4] 7 [7-7]
Indication, n (%)
Hyperlipidemia 23 (66%) 2 (7%) 3 (100%) -
Poor metabolic control 12 (34%) 7 (25%) - 2 (100%)
Muscle involvement - 19 (68%) - -
-Skeletal muscle weakness - 3 - -
-Cardiomyopathy - 6 - -
-Skeletal and cardiac muscle involvement - 9 - -
-Hypotonia - 1 - -
Intervention, n (%)
MCT supplementation/replacement 24 (69%) 6 (21%) - 2 (100%)
High fat diet - 26* (93%) - -
Atkins, ketogenic diet - 5 (18%) - -
ω-3FA supplementation 10 (29%) - - -
Corn oil supplementation 1 (3%) 1 (4%) 3 (100%) -
Months of dietary intervention
Median [range] 8 [1-144] 18 [1-60] 1 [0.5-1] 53 [48-58]
Table 1. Features of published and unpublished cases with hepatic GSD and a dietary lipid manipulation (n=68).
Legend: 1, age at start dietary intervention; available in 85% (58/68) of the cases; MCT, medium-chain 
triglycerides; ω-3FA, omega-3 fatty acids. *; four patients received both MCT and a high fat diet (case 54,55,59, 
and 60), five patients received a ketogenic diet which was also categorized as high fat diet (case 22, 28-31), 
one patient received a high fat diet with corn oil substitution (case 34)17, and one GSDIII patient received high 
fat diet supplemented with D,L-3-hydroxybutyrate (case 32)8.
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Legend: A) Diet composition in GSDI patients before (n=10) and after (n=21) MCT supplementation/
replacement. B) Diet composition in GSDIII patients before (n=10) and after (n= 24) high fat diet. C) MCT 
intake in GSDI patients receiving MCT supplementation/replacement (n=15). D) Lipid intake in GSDIII patients 
receiving high fat diet (n= 18, patients on high fat diet also receiving MCT supplementation were included). 
Data are presented as median [range]. CH, carbohydrates.
Laboratory results
The changes in laboratory parameters in GSDI patients receiving MCT supplementation/replacement 
and GSDIII patients receiving high fat diet are presented in Figure 2 and Supplementary file D.
Triglycerides (TG) concentrations were available in 21 out of 24 GSDI patients receiving MCT 
supplementation/replacement. A decline in TG concentrations was found in 57% (12/21) of the 
GSDI patients, specifically in all adult (4/4) and 36% (5/14) of pediatrics GSDI patients (age not 
available in 3 patients). Pooled data showed a significant decline in TG concentrations after MCT 
supplementation/replacement (9.7 mmol/L ± 9.4 vs 5.9 mmol/L ± 5.1, p<0.05). An inverse correlation 
was found between TG concentrations before intervention and ΔTG (rho= -0.56, p< 0.01; Figure 
2A). In 6 out of 14 children, TG concentrations increased after MCT supplementation/replacement. 
Detectable ketones were reported in 75% (3/4) of GSDI patients (Supplementary File D). In three 
GSDI patients acylcarnitine profile was determined; data showed an increase in acetylcarnitine and 
butyrylcarnitine in two patients, and an increase in palmitoylcarnitine in one patient9.
Creatine kinase (CK) concentrations were available in 73% (19/26) of GSDIII patients receiving 
high fat diet (Figure 2B). Mean CK concentrations decreased in 89% (17/19) of GSDIII patients 
4a
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receiving high fat diet (2070 U/L ± 1634 vs 1078 U/L ± 1148, p<0.001). One patient showed 
an increase in CK concentrations (case 64), however, CK concentrations remained within the 
reference range19. Another patient showed stable CK concentrations (case 65). No correlations 
between ΔCK and changes in macronutrients were found.
Liver transaminases (ALT/AST) were documented in 58% (15/26) of GSDIII patients on a high 
fat diet (Figure 2C-D). In adult GSDIII patients, ALT concentrations decreased in all cases (n=6); 
AST concentrations decreased in 5 patients (83%) and were stable in the sixth patient. In pediatric 
GSDIII patients, ALT concentrations increased in 4 patients (44%), decreased in 1 patient (11%) 
and were stable in 4 patients (44%); AST concentrations increased in 5 patients (56%), decreased 
in 2 patients (22%) and were stable in 2 patients (22%).
Figure 2. Changes in laboratory outcomes by dietary lipid manipulation in GSDI and GSDIII.
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Legend: A) Relation between TG concentration before intervention and change in TG concentration of 
21 individual patients with GSDI on MCT supplementation/replacement. Spearman’s rho correlation 
coefficient = -0.60, p < 0.01. Grey circle; GSDI patient, triangle; GSDIb patient, open symbol; GSDI patient reaching 
TG <6.0 mmol/L2 after MCT supplementation/replacement. ** p < 0.01. B) Relation between CK concentrations 
before intervention and change in CK concentration of 19 individual patients with GSDIII with high fat diet, 
including patients with combined high fat diet and MCT supplementation (n=4). Spearman’s rho correlation 
coefficient = -0.40, p > 0.05. Grey square; GSDIII patient, black square; GSDIII patient receiving combined 
high fat diet and MCT supplementation, white square; GSDIII patient showing CK concentrations within age-
related reference values before and after dietary lipid manipulation19. C) Measured blood ALT concentrations 
in GSDIII patients before (circle) and after (square) the introduction of a high fat diet. D) Measured blood AST 
concentrations in GSDIII patients before (circle) and after (square) the introduction of a high fat diet.
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Imaging and clinical outcomes
Longitudinal data on exact liver size (assessed with ultrasound) were available for three GSDI 
patients receiving MCT supplementation/replacement: one adult GSDIa patient (stable liver size, 
regression from 2 to 1 adenoma), one child with GSDIa (increased liver size, progression from 1 
adenoma to 2 adenomas), one child with GSDIb (increased liver size, no adenoma).
Among GSDI patients receiving MCT supplementation/replacement, improved height SDS 
was reported in 9/16 (56%) children. Among GSDI children, 50% showed stable (normal) BMI and 
20% showed a beneficial change in BMI. Two adult GSDI patients showed improved BMI and one 
adult patient had a stable (normal) BMI. One GSDI patient showed xanthomas disappearance 
after MCT supplementation (case 17,18; considered as one patient)15,16. IVSd Z-scores decreased in 
pediatric GSDIII patients with a high fat diet (n=7, p<0.01; Figure 3), but not in adult GSDIII patients 
(n=4, Supplementary file C). There were no correlations between the change in IVSd Z-scores and 
changes in macronutrients. Data on muscle ultrasound and muscle function tests were available 
in two adult GSDIIIa patients on a high fat diet with MCT replacement (case 54, 55). There was no 
effect on muscle density. Muscle strength as assessed with dynamometry improved only for case 
54. Subjective improvements of exercise tolerance and/or muscle strength were reported in 78% 
(14/18) GSDIII children and 50% (4/8) GSDIII adult patients on high fat diet. Among pediatric GSDIII 
patients receiving a high fat diet 18% (2/11) showed improved height SDS, 64% (7/11) showed 
stable height SDS and 18% (2/11) showed decreased height SDS. All pediatric GSDIII patients 
showed normal BMI (60% stable, 40% normalized). BMI was stable in all GSDIII adult patients.
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Legend: Measurements are displayed as Z-scores. GSDIIIa subjects are noted with symbols according to E-% 
of fat. Grey column represents range of normal Z-scores.
Side effects and concomitant medication
Side effects were reported in six patients. Hypoglycemia is a common symptom in GSD and 
was reported in two GSDIa patients on MCT supplementation, and two GSDIII patients on a 
high fat diet. Specifically, one pediatric GSDIa patient experienced hypoglycemia and ketonuria 
4a
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during two episodes of severe gastroenteritis (case 5)7 , one GSDIa adult presented with isolated 
hypoglycemia before and after MCT supplementation (case 47), one pediatric GSDIIIa patient (case 
57) reported isolated hypoglycemia three years after the start of a high fat diet, and one pediatric 
GSDIIIa patients (case 58) presented with an isolated hypoglycemia one year before and two years 
after start of a high fat diet. Other reported side effects were gastro-intestinal symptoms in an 
adult GSDIa patient (case 38) on MCT replacement and worsening of epistaxis in a GSDI patient 
receiving omega 3-FA supplementation20. Four GSDI patients received fenofibrate treatment that 
was started before dietary intervention (case 7, 43, 45 and 51).
DISCUSSION
Complex carbohydrates and, for ketotic GSD patients, protein enrichment are the cornerstones 
of dietary management in hepatic GSD. The role of lipids has not been systematically assessed 
and the current guidelines do not provide clear indications for their use2–6. This is a systematic 
literature study and retrospective international multi-center cohort study presents that a high 
fat diet could be considered in pediatric GSDIII patients with cardiomyopathy, but yet there is 
insufficient data supporting dietary lipid intervention in remaining hepatic GSD patients and 
indications. The significant reduction in blood CK concentrations and subjective improvement in 
muscle strenght reported in GSDIII patients necessitates further quantification of the effect of a 
high fat diet on muscle quality and function. Also liver function, morphology and growth should 
be carefully monitored under a high fat diet given the potential impact on underlying liver disease.
Before discussing the results, some methodological issues need to be addressed. The analysis 
and interpretation of the data were hampered by large variation in age, dietary intervention (e.g. 
lipid amount, high fat diet alone or together with lipid supplementation), duration of intervention, 
and outcome parameters. The published cases presented in this study (n=37) were retrieved from 
case reports or small cohort studies (describing less than five patients); therefore, these data were 
likely affected by selection and publication bias. Four (40%) of the full-text papers included in this 
study were published before 199515–17,20. No significant decline in TG concentrations was observed 
when case reports published before the introduction of international guidelines were excluded (8.3 
mmol/L ± 6.7 vs 5.8 mmol/L ± 6.0, p=0.24). It is recognized that metabolic control has improved 
with increasing knowledge on dietary management/glycemic control and the introduction of 
management guidelines21. Also, the possible beneficial role of a more compliant dietary scheme 
during dietary intervention should be considered. Finally, ascertainment bias extends to healthcare 
professionals attending a GSD conference.
The main indication to start with a lipid manipulation in GSDIII patients were cardiomyopathy, 
skeletal myopathy or a combination of both. Lipids became the main macronutrient in GSDIII 
patients at the expense of carbohydrates. Interestingly, cardiac hypertrophy, as quantified by IVSd 
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Z-scores, decreased only in pediatric GSDIIIa patients. We hypothesize that an early switch to high 
fat diet can reverse -or at least decrease- the cardiac glycogen storage. Moreover, results showed 
decreased CK concentrations in 89% of GSDIII patients in accordance with literature8,10,11, and 
improved subjective strength in most patients. Increased blood CK concentrations reflect muscle 
damage which may partially be influenced by exercise. Whether the beneficial effect of a high fat 
diet on CK concentrations is caused by a lower carbohydrate intake -and thus less accumulation 
of abnormal glycogen in muscle tissue- or due to the properties of fat to supply alternative energy 
substrate for muscle remains to be investigated. Notably, most of the GSDIII patients included 
in the present study received a combination of a high fat and high protein diet. Therefore, these 
changes in macronutrient composition could also partly account for the beneficial effect on 
cardiac hypertrophy and CK concentrations. Nevertheless, protein intake was comparable before 
and after intervention in GSDIII patients in the present study (Figure1B).
The development of chronic liver disease is an important concern in ageing GSDIII patients. 
Although the prevalence of hepatocellular carcinoma was low in the International Study on GSDIII22, 
severe and progressive liver fibrosis has been described at early ages23. Only one publication 
describing high fat diet in two GSDIIIa patients documented data on liver transaminases (case 
24, 25)10. Interestingly, we found that ALT increased in 44% (4/9) of pediatric GSDIII patients, but 
decreased in all adult GSDIII patients. After dietary lipid manipulation, the concomitant decrease in 
carbohydrate intake could theoretically lead to less glycogen accumulation in the liver. It remains 
speculative if these age-specific effects are part of the natural history or influenced by dietary 
lipid manipulations. However, under these circumstances, careful monitoring and follow-up is 
warranted for liver complications such as hepatosteatosis, liver inflammation and hepatocellular 
carcinoma24.
The pathogenesis of hyperlipidemia in hepatic GSD is incompletely understood and likely 
different between nonketotic and ketotic GSD types. Inhibition of mitochondrial carnitine 
palmitoyltransferase 1 (CPT-1) by accumulated malonyl co-enzyme A is expected 12 and arrested 
very-low-density lipoprotein catabolism is demonstrated in GSDIa patients25. Theoretically, MCT 
could bypass the metabolic block of long-chain fatty acid oxidation (FAO) thereby supplying FAO 
and providing an additional source of energy26. Variability in effect of MCT on TG concentrations 
among patients might be due to variable compliance, dietary scheme (e.g. MCT only at night), age, 
severity of hyperlipidemia and concurring factors (e.g. apolipoprotein variants). In this respect, the 
lipid lowering effect of MCT administration requires further mechanistic investigation.
Dietary lipid manipulation was started in childhood in 80% of the cases. This may suggest 
that besides the importance of glycemic control, management of hepatic GSD patients is 
increasingly focused on the correction of secondary metabolic disturbances and extrahepatic 
manifestations. Hepatic adenomas with the risk of undergoing malignant transformation are 
a great concern in ageing GSDI patients27. Hypertriglyceridemia is an important risk factor for 
adenomas28 and improvement in TG concentrations is associated with regression of adenomas29. 
4a
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In the present study, one GSDIa patient (case 51) developed a liver adenoma while receiving MCT 
supplementation; in this patient MCT failed to decrease TG concentrations.
Side effects were reported in six patients, including gastrointestinal complaints and (mostly 
mild) hypoglycemia, an intrinsic symptom in hepatic GSD patients30. ‘Side effects’ was not a 
specific parameter in our data table, and therefore the side effects reported in this study could be 
an underrepresentation. Previous mentioned concerns regarding MCT in GSDI patients are the 
unknown consequence towards the elongation of fatty acids or gluconeogenesis12. Increased TG 
concentrations after MCT supplementation have been reported in GSDIII patients31. However, in 
the present study, the majority of GSDIII patients received a high fat diet rather than MCT. As high 
fat diets have been associated with an increased risk of osteoporosis32 combined with the reduced 
bone mineral density in GSDIII patients33 the long-term effect of dietary lipid manipulations on 
bone status should be carefully monitored.
Recommendations for future dietary intervention studies and follow-up of GSDIII patients 
who start with a high fat diet are summarized in Supplementary File E. The present study 
provides insight in useful and missing outcome parameters when assessing the effect of a 
dietary intervention in hepatic GSD patients. Several additional outcome measures are proposed 
including muscle34–36, bone33, mitochondrial9,37 and enzymatic38 markers. Prospective, long-term 
follow-up studies are warranted to confirm efficacy and safety of dietary lipid manipulations in 
the international GSDIII and further hepatic GSD cohort.
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Supplementary File A. Prisma fl owchart of search strategy. PubMed and Embase were searched using both 
MeSH terms and free text: a. PubMed search: ‘(“Glycogen Storage Disease”[Mesh] OR glycogen storage[tiab] 
OR glycogenos*[tiab]) AND (“Ketogenic Diet”[Mesh] OR “Diet, Carbohydrate-Restricted”[Mesh] OR ((fat[tiab] 
OR fatty*[tiab] OR oil*[tiab] OR atkins[tiab] OR ketogen*[tiab]) AND (diet[tiab] OR diets[tiab] OR dietary[tiab] OR 
dieting[tiab])) OR “triheptanoin” [Supplementary Concept] OR “Triglycerides”[Mesh] OR “Dietary Fats”[Mesh] OR 
“Fish Oils”[Mesh] OR medium chain triglycerid*[tiab] OR MCT[tiab] OR triheptanoin*[tiab] OR omega-3-fatty 
acid*[tiab] OR fi sh oil*[tiab]) NOT ((“Animals”[Mesh] NOT “Humans”[Mesh]) OR animal*[ti] OR rat[ti] OR rats[ti] 
OR mouse[ti] OR mice[ti] ); b. Embase search: (‘glycogen storage disease’/exp OR (‘glycogen storage’ OR gly-
cogenos*):ab,ti) AND (‘ketogenic diet’/exp OR ‘low carbohydrate diet’/exp OR ((fat OR fatty* OR oil* OR atkins 
OR ketogen*) AND (diet OR diets OR dietary OR dieting)):ab,ti OR ‘triheptanoin’/exp OR ‘triacylglycerol’/exp OR 
‘fat intake’/de OR ‘fi sh oil’/exp OR (‘medium chain triglycerid*’ OR MCT OR triheptanoin* OR ‘omega-3-fatty 
acid*’ OR ‘fi sh oil*’):ab,ti) NOT ((( ‘animal’/exp OR ‘nonhuman’/exp) NOT ‘human’/exp) OR (animal* OR rat OR 
rats OR mouse OR mice):ti). The search was conducted on the 31th of December 2018. The PubMed search 
revealed 179 articles whereas the Embase search resulted in 388 articles. After the duplicate check a total of 
455 articles could be included for the search strategy. *From this case missing data in the published report 
were collected during the retrospective study part; this case was therefore included as unpublished case (case 
60) in Supplementary File C.
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RECOMMENDATIONS FOR CLINICAL FOLLOW-UP OF DIETARY 
LIPID MANIPULATIONS INPATIENTS WITH GLYCOGEN STORAGE 
DISEASES TYPE III.
Based on: ‘Dietary lipids in hepatic glycogen storage diseases: a systematic literature study, case 
studies and future recommendations.’
Introduction
Prospectively designed dietary intervention studies are strongly needed to strengthen our 
knowledge on dietary management in hepatic GSD. With this recommendations document we 
aim to provide guidance to clinicians and researchers in the field of metabolic disease who intend 
to study a dietary lipid manipulation, either in clinical management or in the setting of a clinical trial.
Target audience
The present recommendation document is addressed to all health care professionals (physicians 
and dieticians) who take care of hepatic GSD patients.
Disclaimer
Recommendations are derived from retrospective data collection. Recommendations only refer 
to dietary lipid manipulations in GSD type IIIa. However, general principles provided here could 
help arranging a dietary lipid manipulation in all hepatic GSD.
To date, recommendations on dietary management from international management guidelines 
are still the key in management in hepatic GSD patients.
Index
A – General study recommendations
B – Recommendation sheet lipid manipulation in GSDIIIa patients
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A - GENERAL STUDY RECOMMENDATIONS
I. Patient selection
1) Reasons to start dietary lipid manipulation
 Development of cardiomyopathy and/or muscle weakness despite optimal dietary regimen1.
2) Rationale to start dietary lipid manipulation
 Reverse/improve cardiomyopathy and/or myopathy
3) Check contra-indications
- Liver and/or kidney dysfunction
- Osteoporosis
- Current pregnancy, or breastfeeding
- Diabetes mellitus (excluding isolated insulin-resistance)
II. Dietary intervention
- Interventions should be standardized. The amount of fat should be uniform (e.g. high-fat diet, 
ketogenic diet) as well as the type of fat administered (e.g. high-fat only, high-fat + MCT) and 
duration of the supplementation.
- Three-day food diaries are recommended to study dietary compliance and analyze exact 
distributions of macronutrients.
- Amount and duration herein suggested are based on the results of the present study (median 
value among patients showing beneficial effect)
III. Outcome measures
Outcome measures should be uniform and blood samples should be taken under similar 
conditions (i.e. specific number of hours after meal and/or specific time during the day). Standard 
outcome markers should be assessed to make future studies comparable. Taking into account 
the results of the present study, specific markers are suggested on the next pages.
Improvement should be defined if:
- [CK] decreased by 10% (or more) or normalized
- IVSd Z-scores decreased or normalized
IV.  Recommendations on safety





1 Guidelines recommend a minimal protein intake of 3 grams per kilogram bodyweight in pediatric 
GSDIIIa patients.
4a
BNW_Irene_V1.indd   131 23-03-20   09:26
132
Chapter 4a
B - LIPID MANIPULATION IN GSDIII PATIENTS
Dietary intervention: high fat diet
Amount: lipids 60% of daily E-% (children 6 g/kg/day, adults 1.7 g/kg/day)
Minimal duration of intervention: 24 months [range: 3 – 60]
Outcome measures:
Clinical markers: height SDS, weight SDS, BMI, clinical picture (e.g. fatigue, exercise intolerance, 
dyspnea, muscle strength), comorbidities, QoL questionnaire, International physical activity 
questionnaire.
Biochemical markers:
- Blood glucose homeostasis: home site continuous glucose monitoring. Number of 
hypoglycemia (n), mean [range] glucose concentration, percentage of the day [glucose] < 4.0 
mmol/L, percentage of the day [glucose] > 8.0 mmol/L. Mean morning ketone concentrations 
(mmol/L) as assessed with handheld device.
- Blood makers: beta-hydroxybutyrate, acetoacetate, triglycerides, total cholesterol, HDL, LDL, 
FFA, insulin, AST, ALT, CK, CK-MB, NT-proBNP, TnT, calcium, phosphorus, alkaline phosphatase, 
parathyroid hormone, calcitonin, osteocalcin, vitamin D, prealbumin, creatinine, estimated 
glomerular filtration rate, vitamins*, minerals*
- urine: proteinuria, microalbuminuria
- metabolic investigations: plasma acylcarnitines, plasma biotinidase, urine organic acids, urine 
glucose tetrasaccharide
Imaging markers: liver ultrasound (liver size in cm, liver longitudinal diameter), cardiac 
ultrasound (IVS thickness, SF, outflow obstruction, diastolic function parameters, left ventricular 
mass), muscle ultrasound, bone mineral density (DXA), liver/heart/muscle MRI*
Muscle markers: six-minute walking test, muscle ultrasound (muscle density for all muscle 
groups), dynamometry (strength Z-scores according to references) *
Dietary markers: diet composition (total Kcal/day, E-% and exact amount (g/kg/day) for each 
macronutrient. Dietary compliance; three-day food diary.
Frequency of follow-up:
Check clinical, blood, and dietary markers monthly for the first 3 months. According to individual 
outcomes frequency of follow-up can be expanded to every 6 months. Specific metabolic 
investigations, muscle markers and imaging measures should be at least assessed at the 
beginning and at the end of the intervention.
* consider
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